CA Patent

CA2899281C — Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia

Assigned to Rigel Pharmaceuticals Inc · Expires 2022-05-31 · 4y expired

What this patent protects

In a preferred embodiment, there is provided a compound for use in treating or preventing autoimmune alopecia, wherein the compound is

USPTO Abstract

In a preferred embodiment, there is provided a compound for use in treating or preventing autoimmune alopecia, wherein the compound is

Drugs covered by this patent

Patent Metadata

Patent number
CA2899281C
Jurisdiction
CA
Classification
—
Expires
2022-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Rigel Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.